Chr. Hansen Holding A/S
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Chr. Hansen Holding A/S is a global bioscience company specializing in the development, production, and marketing of natural ingredients including cultures, enzymes, probiotics, and natural colors primarily for the food, nutritional, pharmaceutical, and agricultural industries. Its product portfolio includes food cultures and enzymes for dairy and other food processing applications; natural colors for food and beverages; probiotics and microbial solutions targeting human and animal health; and plant health products such as bionematicides, biostimulants, and biofungicides. The company serves diverse markets worldwide including Europe, North America, Asia-Pacific, and Latin America. Founded in 1874 and headquartered in Hørsholm, Denmark, Chr. Hansen operates through various subsidiaries and maintains a broad manufacturing and R&D footprint globally. In recent major developments, Chr. Hansen launched its 2025 Strategy focusing on microbial and fermentation technology platforms, emphasizing growth in its Food Cultures & Enzymes and Health & Nutrition segments with innovative product launches including probiotic solutions for food and pet food, expanded plant health solutions, and bioprotection cultures to reduce food waste. The company completed the acquisition of UAS Laboratories in 2020 to strengthen its microbial platform and expand probiotic offerings and manufacturing capabilities in the U.S. In late 2023, Chr. Hansen agreed to divest its global lactase enzyme business to Kerry Group, marking a strategic shift to focus on its core microbial and fermentation technologies. Additionally, Chr. Hansen and Novozymes announced a planned merger to create a leading biosolutions company, advancing their complementary strengths. These initiatives underline Chr. Hansen’s commitment to sustainability, innovation, and expansion across its core bioscience areas with the ambition to contribute significantly to food and health sectors globally.
Shell Signs New Engineering Framework Agreement With Chiyoda
Chr. Hansen: Still Somewhat Undervalued After Its Outperformance
Chr. Hansen Holding A/S (CHYHY) Q4 2023 Earnings Call Transcript
Chr. Hansen Holding A/S Interim Report Q4 2022/23
Chr. Hansen: Not A Great Performance, But Looking Forward
Chr. Hansen Holding A/S (CHYHY) Q3 2022 Earnings Call Transcript
Chr. Hansen Holding A/S (CHYHY) CEO Mauricio Graber on Q2 2022 Results - Earnings Call Transcript
Chr. Hansen Holding A/S' (CHYHY) CEO Mauricio Graber on Q1 2022 Results - Earnings Call Transcript
Chr. Hansen Holding A/S (CHYHY) CEO Mauricio Graber on Q4 2021 Results - Earnings Call Transcript
Chr. Hansen Holding A/S (CHYHY) CEO Mauricio Graber on Q3 FY2021 Results - Earnings Call Transcript
Chr. Hansen Holding A/S Interim Report Q3 2020/21
Extraordinary dividend
Chr. Hansen Holding A/S' (CHYHY) CEO Mauricio Graber on Q1 2021 Results - Earnings Call Transcript
Chr. Hansen Holding A/S Interim report Q1 2020/21
Goldman Sachs Group Upgrades Chr. Hansen Holding A/S (OTCMKTS:CHYHY) to Neutral
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Given Consensus Recommendation of “Hold” by Analysts
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Given “Neutral” Rating at Credit Suisse Group